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Abstract
The genotype-phenotype (GP) map is a central concept in evolutionary biology as it
describes the mapping of molecular genetic variation onto phenotypic trait variation. Our
understanding of that mapping remains partial, especially when trying to link functional
clustering of pleiotropic gene effects with patterns of phenotypic trait co-variation. Only
on rare occasions have studies been able to fully explore that link and tend to show poor
correspondence between modular structures within the GP map and among phenotypes.
By dissecting the structure of the GP map of the replicative capacity of HIV-1 in 15 drug
environments, we provide a detailed view of that mapping from mutational pleiotropic
variation to phenotypic co-variation, including epistatic effects of a set of amino-acid
substitutions in the reverse transcriptase and protease genes. We show that epistasis
increases the pleiotropic degree of single mutations and provides modularity to the GP
map of drug resistance in HIV-1. Moreover, modules of epistatic pleiotropic effects
within the GP map match the phenotypic modules of correlated replicative capacity
among drug classes. Epistasis thus increases the evolvability of cross-resistance in HIV
by providing more drug- and class-specific pleiotropic profiles to the main effects of the
mutations. We discuss the implications for the evolution of cross-resistance in HIV.
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Introduction
A central goal of evolutionary biology is to understand how genetic variation maps onto
phenotypic variation, and ultimately fitness. Many phenotypic traits are complex traits
affected by many genes, as for instance Alzheimer’s disease or type 2 diabetes in humans
(Mackay et al., 2009; Plomin et al., 2009). The genes affecting such traits often affect
other traits as well, and are thus pleiotropic. The way they affect trait variation also often
depends on their interactions with other genes. There is thus pleiotropy and epistasis
in the GP map (Hansen, 2006; Phillips, 2008). The way pleiotropic and epistatic gene
effects are organized within the GP map is expected to play a capital role in the capacity
of living organisms to adapt and evolve (Wagner and Altenberg, 1996; Hansen, 2006;
Wagner et al., 2007; Armbruster et al., 2014). In particular, the modular clustering of
pleiotropic effects among sets of traits allows phenotypic modules to respond to selection
independently from each other, potentially increasing the evolvability of the organism
(Wagner and Altenberg, 1996; Wagner et al., 2007; Armbruster et al., 2014). Trait
genetic integration (i.e., higher density of pleiotropic links within than between modules;
Figure 1B) may be favored when coordinated changes at multiple traits are necessary,
or disfavored when pleiotropic links act as genetic constraints on evolution (leading to
parcellation, see Fig. 1B). Indeed, when several traits are affected by a common set of
pleiotropic loci, as within a module, they become less evolutionary independent because
changes in allelic frequencies at those loci will affect all traits, and changes favorable to
one trait may be detrimental to the other traits (Otto, 2004). This would be the case
if, for instance two traits are genetically correlated while selection acts to change only
one of them, while keeping the other constant. Evolution may break such pleiotropic
constraints, or build them up, if variation in pleiotropy exists at the underlying genes.
Trait integration is often deduced from trait phenotypic or genetic correlations within a
population (Figure 1C) and is expected to reflect the degree of genetic independence of
the traits (Pigliucci, 2003; Armbruster et al., 2014). Genetic correlations among traits are
function of the correlation among pleiotropic mutational effects at the underlying genes
(Figure 1C), among other more transient sources of genetic covariances (e.g., linkage
disequilibrium, drift). Variation in genetic covariation among traits thus depends on
variation in the pleiotropic degree and in the correlation of the effects of pleiotropic
mutations. Which of these two properties of pleiotropic mutations is more likely to vary
and to contribute to trait correlations in natural systems is mostly unknown.
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What role does epistasis play in the evolution of the GP map? Epistasis may cause
pleiotropy to vary at a locus because pleiotropy is also a property of a genetic interac-
tion, be it between two mutations within or between genes. For instance, two mutations
in a gene may have lower pleiotropic degree when alone than when together in the
same sequence (Figure 1A). Epistasis may thus provide the genetic variation necessary
for the evolution of pleiotropy (Guillaume and Otto, 2012; Pavlicev and Wagner, 2012;
Rueﬄer et al., 2012) and restructure genetic correlations among traits to, for instance,
match patterns of trait covariation favored by selection (Jones et al., 2014). These ef-
fects of epistasis may be even more important on the long run than its single trait effect
of altering evolutionary paths to higher fitness peaks (Weinreich et al, 2006; Poelwijk
et al., 2007; Franke et al., 2011) by alleviating pleiotropic constraints on trait evolution.
Epistatic pleiotropy, whereby the pleiotropic degree of a mutation depends on its inter-
action with other mutations (Wolf et al., 2005, 2006), is indeed thought of as a potent
source of variation in pleiotropy and thus an important factor affecting the evolution
of the structure of the GP map of genetically correlated traits (Hansen, 2006; Pavlicev
et al., 2011; Pavlicev and Wagner, 2012).
The goal of our work is to uncover both the distribution of the pleiotropic degree and the
among-trait covariation of mutations and their pairwise interactions affecting multiple
traits to understand the genetic basis and evolvability of phenotypic correlations. Access
to such data is challenging but would enable us to ask how phenotypic modularity is
reflected within the GP map, and vice-versa. We indeed have little evidence so far
that the patterning of the pleiotropic effects within the GP map directly affects the
correlational structure of the phenotypes. For instance, studies of mouse bone structures
show little correspondence between pleiotropic modules of QTL affecting morphological
traits and the genetic variance-covariance structure of those traits (Hallgr´ımsson and
Lieberman, 2008; Roseman et al., 2009). Within module integration of pleiotropic effects
may not cause elevated trait genetic correlation if the underlying genes bear pleiotropic
allelic values that cancel each other because sometimes positive and sometimes negative,
compensating for each other’s effects (i.e., hidden pleiotropy). Simulations confirm that
without correlation of the allelic pleiotropic effects within modules, no clear correlational
pattern will emerge at the phenotypic level despite pleiotropy of the underlying loci
(Polster, 2013).
We use an extensive dataset of fitness measurements of 70,080 patient-derived viral
particles of HIV-1B in 15 different antiretroviral (ARV) drug environments that we treat
as our phenotypic traits (Petropoulos et al., 2000). The fitness effects of the amino-acid
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variants occurring in two genes, the reverse transcriptase and the protease, have been
previously estimated together with their pairwise interaction effects in each environment
(Hinkley et al., 2011). We are thus able to describe the distribution of pleiotropy and
epistatic pleiotropy of the mutations, and the genetic variance-covariance structure of
their single and interaction effects on the 15 drug resistance traits. Previous studies
have found pleiotropy and epistasis in all types of organisms, from bacteria and viruses
to vertebrates and plants, including disease genes in humans (Moore, 2003; Azevedo
et al., 2006; Cordell, 2009). Epistatic interactions have been shown to happen among
mutations within (Weinreich et al, 2006; Ortlund et al., 2007; Hinkley et al., 2011) and
between genes (reviewed in Phillips, 2008), and a few studies have measured genome-
wide distributions of epistasis, mostly in bacteria (Elena and Lenski, 1997) and viruses
(Bonhoeffer et al., 2004). Genome-wide distributions of whole-gene pleiotropy have
also been described in model systems using gene knock-out/-down technique (Giaever
et al., 2002; Dudley et al, 2005; So¨nnichsen et al., 2005). Even so, we are still missing
measurements of the mutational variation in pleiotropy and we only start to apprehend
the extent of epistatic pleiotropy (Wolf et al., 2005, 2006) and its contribution to variation
in trait correlations (Cheverud et al., 1997, 2004; Pavlicev et al., 2008). In contrast, in
this study, we are able to link patterns of mutational variation in pleiotropy, epistasis,
and the co-variation of their effect with patterns of phenotypic trait co-variation. In
other words, we are able to fully describe the structure of the GP map of drug resistance
in HIV-1, which has not been achieved before.
In HIV, pleiotropy and epistasis may play a fundamental role in the evolution of resis-
tance to multiple drugs, or cross-resistance. Since the advent of ARV drug therapies,
resistances to single and multiple drugs have appeared and cross-resistance mutations
have been cataloged (Rhee et al., 2003; Bennett et al., 2009). The acquisition of cross-
resistance mutations may compromise treatment options of combination ARV therapies
and cause substantial threat to the health of HIV infected patients (Bartlett et al.,
2006; Wittkop et al., 2011; WHO, 2012). Understanding the genetic basis of cross-
resistance is thus essential to evaluate its evolutionary potential. However, quantitative
estimates of the evolvability of cross-resistance can only be provided by system-based
approaches. Two such approaches have been applied to the HIV dataset used here
(Petropoulos et al., 2000), which is arguably the largest dataset available. First, Hinkley
et al. (Hinkley et al., 2011) inferred the fitness landscape of HIV-1 in the 15 drug envi-
ronments and showed that within-gene epistasis significantly contributes to the genetic
variation in fitness, while between-gene epistasis contributes very little. Second, Martins
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et al. (2010) showed significant modular co-variation of fitness estimates in the differ-
ent drug environments that matches the different ARV classes; the protease inhibitors
(PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse
transcriptase inhibitors (NNRTIs). What they could not elucidate is the mutational
origin of the clustering because their study remained at the phenotypic level. It is thus
unclear whether phenotypic modularity is contributed by modularity of the main effects
of single mutations or of the interaction effects of double mutations within the two ARV
targeted genes, reverse transcriptase and protease. The structure of the GP map of drug
resistance in HIV-1 is thus not elucidated yet.
In this study, we test whether the GP map of HIV drug resistance traits has a modular
structure that corresponds to the modules of correlated phenotypes. Such a test has
never been performed using concomitant single-gene mutational and phenotypic data.
With the dataset at hand, we show that mutation interactions have modular epistatic
pleiotropic effects that tend to increase the pleiotropy of single mutations, and confer
modularity to mutational pleiotropic effects that match with the pattern of phenotypic
co-variation.
Results
HIV fitness dataset
We use the estimates of fitness effects of mutations within the reverse transcriptase (RT)
and protease (PR) genes of HIV-1 published by Hinkley et al. (2011), based on fitness
measurements of 70,080 patient-derived viral particles of HIV-1B in 15 different ARV
drug environments (described in Methods) and one drug-free environment (Petropoulos
et al., 2000). Briefly, fitness is estimated as the replicative capacity of a test vector
(NL4-3 HIV clone) engineered to undergo only one round of replication and into which
the patient-derived HIV-1B sequences were inserted (full details in Petropoulos et al.,
2000). These fitness values associated with the sequences were then used to estimate
the single and double (pairwise interactions) mutation effects of amino-acid (a.-a.) sub-
stitutions within the two genes (511 in PR and 1348 in RT). To this end, Hinkley
et al. (2011) developed a machine learning approach, generalized kernel ridge regres-
sion (GKRR), to fit a model called MEEP, that predicts the log-fitness of the sampled
sequences (virions) as the sum of the main effects (ME) and pairwise epistatic effects
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(EP) of the set of a.-a. composing each sequence, for each environment separately (see
Methods for details). The GKRR provides estimates of fitness effects of 1859 single mu-
tations (main effects) and 1,090,889 possible pairwise combinations of those mutations
(epistatic effects) (Hinkley et al., 2011). We reduced the epistatic dataset by excluding
non-independent interactions between non-polymorphic sites and interactions present in
less than 10 sequences, resulting in a net total of 556,125 epistatic effects per environ-
ment. Furthermore, we developed a method to estimate the pleiotropy of each single and
double mutation from the GKRR data based on a bootstrapping approach (see Methods
for details). This step is necessary to infer the graph structure of the GP map from an
estimate of the pleiotropic degree (PD) of the mutations and their interactions. A proxy
of the PD of a mutation, or of a gene knock-out, is classically given by the number of
discrete traits on which it has a significant effect (e.g., Dudley et al, 2005; Ostrowski
et al., 2005; Ohya et al., 2005). We obtain the PD of each single and double mutation by
counting their number of significant effects in the 16 environments (PD ∈ [0, 16]) using
their bootstrap confidence intervals in each environment.
Pleiotropy and epistatic pleiotropy
The distributions of the PD of single mutations (PDME) and of epistatic interactions
(PDEP) are shown in Figure 3. The two distributions are fat-tailed and enriched for fully
pleiotropic mutations, that is mutations having an effect in all 16 environments. They are
also significantly different from random distributions obtained by permutation, as shown
in Figure 3 and by Kolmogorov-Smirnov tests (ME: D = 0.7059, p-value= 4.19× 10−4;
EP: D = 0.8235, p-value= 5.13× 10−6).
Epistasis modifies pleiotropy of single mutations by changing their trait repertoire, that
is, by changing the set of traits they significantly affect as a single mutation (PDME)
when in interaction with another modifier mutation. The epistatic repertoire is defined
as PDMEEPi×j = PDMEi ∪ PDEPi×j (see Figure 2). We found that mutations have an
average PDMEEP of 9.22 (±4.89), larger than the average PDME or PDEP (6.14 and
6.45, respectively, see Figure 4). We expect PDMEEP to be larger than PDME or PDEP
because of the additive nature of the MEEP model (i.e., the total effect of a mutation in
interaction with another mutation is the addition of the main and epistatic effect of that
mutation, Figure 2). However, on average, mutation interactions increase trait reper-
toires (Figure 4) above what is expected under pure additivity of the trait repertoires of
the two mutations, for which we expect PDaddMEEP = 8.81 (Wilcoxon, p < 2.2 × 10−16).
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The additive expectation is obtained as the union of the repertoires of the two inter-
acting mutations: PDaddMEEP = PDMEi ∪ PDMEj . Departures from this expectation are
caused by addition of traits that are specific to the mutation interaction (i.e., the private
traits of the interaction, see Figure 2), or subtraction of traits not affected by the inter-
action. Decomposition of PDMEEP into its additive and non-additive components shows
that, on average, epistasis causes an additive increase of trait repertoires of 1.62 traits
and a non-additive increase of 2.42 private traits, thus summing to an average epistatic
increase of about 4 traits. These changes are smaller than their random expectations
(2.09 and 3.25 for additive and non-additive increases, respectively) at P < 0.0001, ob-
tained from 10,000 randomizations (see Methods). The additive increase is also smaller
than expected under complete additivity (3.63), showing that some traits are not af-
fected in interaction. Finally, 68% of the 73% of mutations that show an increase of
PD in interaction (or 50% of all mutations) do so by obtaining private traits from their
interactions.
Structure of the GP map of fitness among drugs
The structure of the GP map of phenotypic traits is often deduced from the pattern
of trait genetic covariation under the premises that genetic covariation is a reflection
of the underlying organization of pleiotropic allelic effects. To test for this correspon-
dence, we, first, compare covariance matrices of main and epistatic effects of mutations
with the observed covariance matrix of virion fitness values and, second, test whether
allelic pleiotropic effects form modules similar to the modules of covariation of fitness
values among genotypes, that is, at the phenotypic level. The covariation of mutational
pleiotropic effects is conventionally reported as the M-matrix, the mutational variance-
covariance matrix (Camara and Pigliucci, 1999; Estes et al., 2005). We report estimates
of the two M-matrices of main and epistatic effects calculated as the within environ-
ment variance (on the diagonal) and between-environment covariance (off-diagonal) of
mutational effects (main or epistatic) and test whether the genetic covariation of the
phenotypic traits stems directly from the pattern of mutational covariation. We thus
compare M-matrices with the G-matrix holding the variance-covariance structure of the
70,080 fitness (genotypic) values in the 16 environments. G-matrices hold the within
environment variances and between environment covariances of sequence fitness values
on and off the diagonal, respectively. Furthermore, to better appreciate the importance
of epistasis in structuring the GP map of drug resistance, we compare three G-matrices
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with each other: the SEQ G-matrix obtained from the original fitness estimates of the
70,080 sequences, the ME G-matrix obtained from the reconstructed fitness values of
the sequences using estimated main effects only, and the MEEP G-matrix obtained from
the predicted sequence fitness values using the full MEEP model.
Viral fitness is modular among drug classes
Viral fitness clusters among drug classes, as shown by patterns of genetic correlations
(Figures 5) and principal component analysis (PCA) of the G-matrices (see Figures 6 and
S5-7). The NRTI class has greater drug specificity with two submodules, one composed
of the cytidine (3TC) and guanosine (ABC, ddI) analogs and the other of the thymidine
(d4T, ZDV) and adenosine (TFV) analogs (see also Martins et al., 2010)). Overall,
correlations are high (Table 1), particularly among NNRTIs (0.92) and PIs (0.89). The
same modular pattern as in the SEQ G-matrix is found in the MEEP G-matrix (Figure
5). The ME sequence fitness G-matrix, however, shows much higher correlations among
all drug classes, without clear modular structure, suggesting a larger integration of the
GP map at the level of main effects.
The lack of modularity of the main effects and the similarity between the SEQ and
the MEEP viral fitness are confirmed when using evolutionary metrics to compare the
G-matrices (see Methods). In particular, the autonomy of a G-matrix measures the
degree of genetic modular integration of phenotypic traits: higher autonomy is reached
when traits within modules are more strongly genetically related to each other than to
other traits in other modules (Hansen and Houle, 2008). We find that the MEEP and
SEQ matrices have the highest autonomy and thus better integrated modules than the
ME matrix (Table 2a). Second, the effective dimensionality nD provides a weighted
modularity measure representing the number of independent trait modules with equal
variance (Kirkpatrick, 2009). Here, the MEEP matrix has the highest number of in-
dependent trait dimensions, followed by SEQ and ME (Table 2a). Finally, the random
skewers approach provides a matrix similarity measure in the form of a vector correlation
coefficient (Cheverud, 1996) (see Methods). This analysis shows that the MEEP and
SEQ matrices are the most similar among the three matrices (Table 2c). The MEEP
matrix then captures most of the correlation structure present in the SEQ matrix and
provides a good estimate of the multivariate trait structure of viral fitness, although it
exacerbates the modularity found in the original fitness data.
8
 at Zentralbibliothek on Septem
ber 27, 2016
http://m
be.oxfordjournals.org/
D
ow
nloaded from
 
The PCA confirms the clustering among drug classes (Figure 6), although drug classes do
not differentiate along the first PC, with roughly equal loadings of the 16 environments.
PC1 explains 50% of total fitness variation in the SEQ dataset (Figure 6), and 84%
and 47% for ME and MEEP, respectively. PC1 is similar to a size vector discriminating
high versus low average fitness values of generally highly correlated sequence fitness
values among drugs. PC2 nevertheless differentiates the NNRTIs from the other drug
environments, especially within the SEQ dataset, while PC3 further differentiates the
NRTIs from the PIs and NNRTIs, although mainly in SEQ and MEEP. Interestingly, that
third PC differentiates among the two NRTI sub-groups in the MEEP dataset, where
3TC, ABC, and ddI have negative loadings on PC3. That general drug-class modular
structure is largely confirmed by hierarchical clustering analysis (see Figures S5-7), which
more clearly shows the two NRTIs sub-groups. The stability of the PCs is very high
when tested by sub-sampling and bootstrapping (see Supplementary Information).
Mutational covariation is less modular than viral fitness covariation
The modularity of trait covariation within the G-matrix may have two non-exclusive
sources: i) elevated correlation of pleiotropic allelic values among traits within modules,
ii) clustering of pleiotropic effects within modules. The previous results suggest that
EP should differ from ME in at least one of those two aspects, which we evaluate by
comparing their M-matrix and by investigating the modularity of their respective GP
map.
The M-matrix of the main effects is very close to its G-matrix (Table 2a-b, first column),
while the EP matrix has lower nD and autonomy than the MEEP matrix (Table 2a-
b, second column). The two M-matrices have similar modularity, although epistatic
effects have slightly higher autonomy (Table 2b). Epistatic effects are then much less
modular than the modularity of the MEEP data would suggest. Consequently, the
covariation of mutational epistatic effects cannot explain the modular covariation found
among genotypes in the MEEP or SEQ G-matrices. We thus speculate that it is the
combination of main and epistatic effects within the observed sequences that contributes
to the higher modularity seen in the MEEP and SEQ data. That combinatorial aspect
of the data is given by the graph structure of the GP map and thus depends on the
distribution of pleiotropy of the main and epistatic effects among the traits, which we
evaluate next.
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Epistatic pleiotropic effects are more modular than main effects
To measure the clustering of main and epistatic effects within the GP map, we use the
parcellation statistic MP of Mezey et al. (2000). MP measures the lack of pleiotropic
effects between non-overlapping sets of traits (modules). We found that the main effects
are significantly less modular (MP(ME) = 3734, P = 0.0018) and the epistatic effects
more modular (MP(EP) = 1, 624, 637, P < 0.0001) than expected by chance, based on
comparison with randomized sets of ME and EP within environments for a four-module
partitioning of the data (see Methods). Furthermore, epistatic effects have much larger
standardized parcellation than main effects, with MˆP(ME) = −2.85 and MˆP(EP) = 535.74
(see Methods). Among all possible clustering of the 15 drug traits, there will be some
that maximize the parcellation of the ME data compared to randomized sets. Instead
of conducting an exhaustive search, we tested two other trait combinations suggested
by the clustering analysis: a two-module clustering {{NNTRIs}–{NRTIs + PIs}} and a
three-module clustering {{NNTRIs}–{3TC, ABC, ddI}–{TFV, ZDV, d4T, + PIs}} (see
Figure S7). The parcellation of ME is significantly larger than expected by chance for
the two-module case (P < 0.0001), but significantly smaller for the three-module case
(P = 0.0003). The parcellation of EP is always significantly larger with P < 0.0001.
Together, this shows that EP form well supported modules that match those found in
the viral sequence fitness data, while ME cluster among a smaller partitioning of two
modules, confirming that pleiotropy is less modular for main than for epistatic effects.
Epistatic effects trade-off more among drug classes
Fitness trade-offs among drug classes are not clearly apparent from the analysis of cor-
relational patterns: the pairwise genetic correlations between drug environments are
positive and often large. Trade-offs might, however, exist and explain part of the vari-
ation in genetic correlations. Indeed, the proportion of antagonistic EP between two
drug environments (i.e., positive in one environment and negative in the other) is larger
in drug pairs between (5.2%) than within (0.7%) drug classes, on average (Wilcoxon:
p = 8.48 × 10−12). Main effects show lower proportions of antagonistic effects in drug
pairs, with 1.5% between and 0.3% within drug classes on average. The difference re-
mains when accounting for the net effects of the mutations, calculated by summing main
and epistatic effects of each interaction (1.5% between drug classes and 0.49% within,
Wilcoxon: p = 1.42× 10−8). Interestingly, the higher proportion of antagonism between
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drug classes is largely caused by the NNRTI mutations with the other drug classes
(8.8% and 2.5% for EPs and net effects, respectively), compared to the level of antag-
onism among PIs and NRTIs (1.6% and 0.55% for EPs and net effects, respectively).
Moreover, the proportions of pairwise antagonistic EP are strongly negatively corre-
lated to the pairwise correlations of fitness values in the SEQ matrix (rpearson = −0.77,
t103 = −12.16, p < 2.2 × 10−16). By introducing variation in the sign of pleiotropy
in addition to variation in its extent, epistasis causes lower correlations among drug
environments because of larger trade-offs in net mutational fitness effects.
More highly correlated traits are more genetically integrated traits
Is the correlation of fitness values within drug classes (phenotypic integration) indica-
tive of the degree of pleiotropy of the mutations (genetic integration)? We looked at
two aspects of mutation pleiotropy, i) the proportion of significant mutations that are
fully pleiotropic in each drug class (i.e., have PD = 3 in NNRTIs, and PD = 6 in NRTIs
and PIs), ii) the average pleiotropic degree of the significant mutations relative to the
maximum pleiotropy in each drug class (i.e., ‘relative’ pleiotropy in Table 3). Among
the three classes, NNRTIs have the highest average correlation of fitness values, followed
by PIs and NRTIs (Table 1). Accordingly, single and double mutations with significant
effects in NNRTIs are more fully pleiotropic and have a higher average pleiotropic de-
gree than mutations in PIs, and in NRTIs (Table 3). Therefore, more phenotypically
correlated traits are here also more genetically integrated traits, with regards to the
among-trait density of pleiotropy of their underlying mutations. Together with results
from the previous section, phenotypic integration is supported by more pleiotropic links
and less antagonistic mutational effects within than between drug classes.
Intra versus inter-genic epistasis
Until now we have kept all epistatic interactions within and between reverse transcriptase
and protease. To our knowledge, it has not been investigated whether mutations within
reverse transcriptase may affect the inhibitory effects of drugs targeting protease, and
vice versa. Hinkley et al. (2011) tested for the effect of inter-protein epistasis but found
little influence of inter-genic interactions on the overall variation in viral fitness within
drug environments. By removing inter-genic interactions, we find that the intra-genic
EP M-matrix has slightly lower modularity (nD = 1.06; 95% CI = [1.064, 1.067]), with
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unchanged autonomy (a¯ = 0.07; 95% CI = [0.067, 0.073]) compared to the full EP M-
matrix (Table 2). Recalculating sequence fitness with intra-genic interactions only in
the MEEP model further shows that inter-genic EP have little effect on the modularity
(nD,intra = 2.08; 95% CI = [2.06, 2.09]) and autonomy (a¯intra = 0.13; 95% CI = [0.132,
0.134]) of the MEEP G-matrix. The structure of the GP map of drug resistance is thus
little affected by inter-genic epistasis between RT and PR.
Discussion
Our analysis of the genetic co-variation of fitness of HIV-1B among ARV drugs confirms
that there exists high potential for the evolution of cross-resistance. Evaluation of the
response of HIV to selection imposed by multiple ARV treatments can be conducted
using quantitative genetics theory based on the genetic variance-covariance matrix (the
G-matrix) of fitness in multiple environments (Falconer, 1952; Lande, 1979; Via and
Lande, 1985). As first noted by Falconer (1952), considering the genetic correlation
between trait values in two different environments is not different from the genetic cor-
relation of two different traits in the same environment. The differential environmental
effects of the single and double mutations are thus rightly interpreted as pleiotropic ef-
fects structuring the GP map of fitness in multiple environments. In HIV, we expect a
positively correlated response of cross-resistance to multiple ARV drugs because the ma-
jority of genetic variation in fitness lies along the first PC of the SEQ G-matrix, which is
shared among all HIV fitness traits. This is even more true for within drug class cross-
resistance, especially within NNRTIs and PIs, which are more correlated and can be
seen as near-identical traits. Alternatively, a weaker cross-resistance is expected for HIV
evolving under less correlated ARV treatments, as when taken from two different ARV
classes or from the two different sub-modules within the NRTIs. It is indeed known that
NRTIs have higher drug-specific resistance mutations than other ARV classes (Harrigan
and Larder, 2002; Martins et al., 2010; Arts and Hazuda, 2012).
From the same token, drug combinations with the lowest potential for cross-resistance
evolution are combinations with lowest pairwise or three-way correlations, when mim-
icking combination therapies. Based on our results, combinations of one NNRTI with
a PI would have lowest potential for cross-resistance, as would one NNRTI with an
NRTI. Within the NRTI class, combinations of TFV with either 3TC or ABC would
also minimize the potential for cross-resistance. Interestingly, recommendations from
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the International AIDS Society (Hammer et al., 2008) precisely involve combinations of
EFV (NNRTI) with two NTRIs such as TFV with 3TC or ABC, or one RTV-boosted
PI (LPV) with two of these NRTIs. Our predictions are in line with those recom-
mendations, although NNRTIs would seem more adequate in combination with PIs.
Nevertheless, from our data, TFV is the NRTI with lowest correlations with the PIs.
Of course, medical recommendations take more criteria in consideration than the po-
tential for cross-resistance evolution from in-vitro data. For instance, each drug has
its own pharmacokinetics and side effects, and may elicit specific combinations of resis-
tance mutations, especially among NRTIs (Ali et al., 2010; Cihlar and Ray, 2010; Arts
and Hazuda, 2012). This, in part, justifies the fact that we kept all drug environments
separate, although NNRTIs and PIs could be considered as single trait-environments
based on their high within module average correlations, which would lower the average
pleiotropic degree.
About measures of pleiotropy
We have measured pleiotropy by performing an environment-wise exclusion of non-
significant mutational effects under the rational that nearly neutral mutations of small
effects can be discarded because not significantly contributing to fitness variation in a
given environment. This approach is expected to provide an acceptable proxy of the
pleiotropic degree of a mutation, or a gene, when detection thresholds are not too low
(Wagner and Zhang, 2012). The advantage of this measure is to correspond to the defini-
tion of pleiotropy used in theoretical studies as being the number of discrete phenotypic
traits that are affected by a mutation (Fisher, 1930; Chevin et al., 2010; Lourenc¸o et al.,
2011). Its evolutionary properties are thus well understood. It may, nevertheless, lead
to a downward-biased estimate of pleiotropy resulting in the characteristic L-shaped PD
distribution found previously because of low detectability of mutational effects of other-
wise fully pleiotropic mutations (Hill and Zhang, 2012). Although our PD distributions
may also be biased towards lower values, they drastically differ from previous distribu-
tions by their high frequency of fully pleiotropic mutations (Figures 3). That shape is
not predicted as an outcome of detection bias, even when genetic correlations among
traits are high (Hill and Zhang, 2012). Furthermore, the shape of the PD distributions
is robust to our significance filtering because not affected when using only the most or
the least frequent mutations. A bias may exist because mutation frequency is strongly
negatively correlated with the size of bootstrap confidence intervals (see Methods) and
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more frequent mutations may thus be more pleiotropic. Yet, PDME of the most frequent
mutations (i.e., 403 out of 404 a.a. of the consensus sequence) has the same median of
2 traits and same distribution with a similar enrichment of fully pleiotropic mutations
as the full distribution (Figure S1). Similar PD distributions are found for less frequent
mutations and for interactions (Figures S2-3). In sum, given that non-pleiotropic muta-
tions have lower absolute effect sizes than mutations with large PDs, we have effectively
eliminated mutations that would, on average, less affect fitness variation in the pres-
ence of selection than more pleiotropic mutations (Figure S4). Altogether, this gives us
confidence that our PD estimates are robust and biologically meaningful.
General implications
Studying mutations within two essential genes of a virus allowed us to uncover a direct
link between mutational variation in pleiotropy and the pattern of covariation among
the phenotypes. This relationship is not expected to be as direct in higher organisms
where the ontogeny of phenotypes involves multiple loci and intermingled developmental
processes, which may rewrite the character relationships in slightly different ways at each
developmental stage. In this ‘palimpsest’ ontological model (Hallgr´ımsson and Lieber-
man, 2008), the influence of the underlying genes is obscured by the constant rewriting
of the phenotypes. The best known example is the mouse cranial and mandibular mor-
phological traits, where pleiotropic effects of mapped QTL show significant modularity
relative to basal developmental units (Mezey et al., 2000) but not to phenotypic units
(Roseman et al., 2009). In a simpler organism like HIV, the influence of the genes is
directly integrated into phenotypic variation avoiding being drowned out by a succes-
sion of developmental processes. Nevertheless, a similar direct relationship between GP
map and phenotypic structures may be expected in higher organisms for more basal
phenotypes. An example would be molecular phenotypes, such as gene expression traits
where co-variation in expression may be a direct function of the activity of pleiotropic
gene regulatory elements. Recent transcriptomics studies support that idea and have
uncovered heritable variation of gene expression in a few organisms (e.g.: Drosophila
melanogaster (Ayroles et al., 2009); three-spine sticklebacks (Leder et al., 2015)), and
indirectly suggest the presence of pleiotropy in gene regulation by reporting significant
genetic covariance in gene expression (e.g., in D. serrata: McGuigan et al., 2014).
The extent of epistatic pleiotropy in other organisms is little known beside a few QTL
studies in mice (Wolf et al., 2005, 2006), in which a small number of epistatic interactions
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among QTL for morphological traits were shown to contribute less to the phenotypic
covariance of the traits than single pleiotropic QTL, and did not change the trait co-
variances. In contrast, we show a large effect of epistatic pleiotropy on trait covariation.
Moreover, we found that although a large proportion of single mutations do not signifi-
cantly affect fitness in any environments, they will gain significant effects in interaction
and change the pleiotropic effects of their interacting partners. Such mutations can
be viewed as modifiers of pleiotropy with potentially large effects on trait covariances
(Pavlicev and Wagner, 2012). Similar effects have been found by mapping loci that affect
the relationship between traits but remain hidden to the analysis of single effects. Such
relationshipQTL have been shown to affect the trait covariation of mice morphological
traits (Cheverud et al., 2004; Pavlicev et al., 2008). Interestingly, although our study
drastically differs in scope and scale, we show that the same phenomena take place in
organisms as different as a virus and a mouse.
Our study contributes to better understand the relationship betweenM- andG-matrices.
Little is known about their correspondence in living species, and direct estimates of M-
matrices are scarce (but see Camara and Pigliucci, 1999; Estes et al., 2005; Houle and
Fierst, 2013). The correlation of the allelic effects of pleiotropic genes encapsulated in
the M-matrix has important evolutionary consequences because, if non-random, it cre-
ates stable patterns of genetic and phenotypic correlations among phenotypic characters
(Jones et al., 2003) that override the effects of other sources of genetic covariance among
pleiotropic allelic effects (e.g., linkage (Lande, 1980), drift (Griswold et al., 2007), mi-
gration (Guillaume and Whitlock, 2007), correlational selection (Jones et al., 2003)).
The correlational pattern of phenotypes then depends on how much the structure of
the M-matrix translates into heritable genetic covariation of the traits, encapsulated
in the G-matrix. We show that the correlational structure within the M-matrices of
main and epistatic effects are poor predictors of the covariation of fitness among drug
environments. Therefore, patterns of trait integration here depend on the distribution
of the pleiotropic effects among the traits within the GP map. This indicates that the
precise structure of the GP map cannot be ignored as a cause of trait covariation or
genetic constraints, and, hence, as a means of their evolution by modification of gene
pleiotropy (Guillaume and Otto, 2012; Pavlicev and Wagner, 2012).
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Conclusions
By studying phenotypic variation and its underlying mutational variation, we were able
to link phenotypic with pleiotropic modularity. We showed that in HIV-1, a modular
epistatic GP map leads to a modular phenotype. The main effects also play an important
role by quantifying the effects that are shared among environments. They, however, lack
modularity in the correlations and in the patterning of their pleiotropic effects within
the GP map. Epistasis modulates these effects and although it increases pleiotropy, it
does so in a modular fashion, and provides more drug-specific and class-specific profiles
to viral fitness. Our findings have strong implications for our understanding of the
evolutionary potential of drug resistance against multiple drugs in HIV. More generally,
they suggest that epistasis may play a fundamental role in shaping the evolvability of
living organisms by directly affecting the structure of the GP map and the strength of
genetic correlations of phenotypic traits.
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Materials and Methods
Experimental data
Our analyses are based on a sample of 70,080 patient-derived HIV-1 sequences assayed
for fitness in 16 different environments: one drug-free and 15 in presence of one antiretro-
viral drug (Petropoulos et al., 2000). The replicative capacity (fitness) of each sample
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was measured by inserting the full sequence of the protease gene (99 amino acids) and
most of the reverse transcriptase gene (amino acids 1-305) of the patient-derived virion
into the backbone of an HIV-derived test vector used for routine drug resistance test-
ing. The test vector is based on the NL4-3 molecular HIV clone and has been modified
such that it undergoes only one round of replication (full details are in (Petropoulos
et al., 2000)). The fitness of each sequence is the number of virus progeny produced
after one replication cycle relative to that of the base test vector, and provides an esti-
mate of viral fitness in each environment. The 15 drugs used belong to three different
classes: protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and
non-nucleoside reverse transcriptase inhibitors (NNRTIs). The six PI drugs are ampre-
navir (AMP), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), ritonavir (RTV), and
saquinavir (SQV), the six NRTI drugs are abacavir (ABC), didanosine (ddI), lamivu-
dine (3TC), stavudine (d4T), zidovudine (ZDV), and tenofovir (TFV), and the three
NNRTI drugs are delavirdine (DLV), efavirenz (EFV), and nevirapine (NVP). For each
drug, the replicative capacity of a virus on drugs was given by the interpolated value
measured at the drug concentration at which the NL4-3 based control virus has 10%
of its replicative capacity in the absence of drug (the IC90 for NL4-3 was used as the
reference drug concentration for every subsequent measurement).
Estimates of single and double mutation effects
Amino acid sequences of the protease gene and the partial reverse transcriptase gene
were obtained by population sequencing for all virus samples included in this analysis
(Petropoulos et al., 2000). Because of this population sequencing, sequences are defined
in terms of probabilities of allele occurrences for each locus. The effects of all single and
double mutations present in the sequence dataset were then estimated using a generalized
kernel ridge regression (GKRR) procedure (Hinkley et al., 2011). In brief, the GKRR
is a machine learning approach fitting a general linear model in which the number of
parameters to estimate by far outnumbers observation points. It avoids over-fitting of
the model by using a training sub-dataset completely independent from the sub-dataset
from which the parameters are estimated. The model fitted by Hinkley et al. (Hinkley
et al., 2011), called MEEP, is:
log(Wi) = I +
NM∑
j=1
sijmj +
NE∑
k=1
sikk,
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where Wi is the replicative capacity (fitness) of sequence i, mj represents the main
effect (ME) of the jth amino-acid variant and sij is the probability of that variant
occurring in a randomly selected sequence from the population of sequence i. Similarly,
k represents the interaction epistatic effect (EP) of the k
th combination of variants and
sik is a variable that accounts for the presence or absence of that combination of variants
in the sequence. The s parameters may be different from 0 or 1 because of population
sequencing of the HIV viral sequences and the possible ambiguities caused by site-specific
amino-acid polymorphism. I, the intercept, represents the log fitness of the reference
sequence of the test vector (see details in (Hinkley et al., 2011)). In total, 1859 alleles are
present at the 404 amino-acid positions, with 1,090,889 possible interactions. Among
these, we excluded non-independent interactions between non-polymorphic sites and
those interactions present in less than 10 sequences, resulting in a net total of 556,125
epistatic effects. Amino-acid variants with less than ten copies in the whole sequence
dataset were also excluded in Hinkley et al. (2011).
Bootstrapping of GKRR estimates
To provide an estimate of the accuracy of the GKRR method to detect small effects, we
bootstrapped the MEEP model by resampling the fitness of each viral sequence from
the observed values, with replacement. We performed 1000 bootstraps in the NODRUG
environment. Because the bootstrap confidence intervals (CI) are strongly correlated
among drug environments, we generated 400 bootstrap estimates in the EFV, 3TC, and
LPV drug environments, hence bootstrapping one drug per drug class. The number
of bootstraps is limited because of the extremely high computational demand of the
procedure, and because little variation in confidence interval sizes is detected above 200
bootstrap replicates. Moreover, the correlation in per-mutation CI sizes among those
three drug environments are highly correlated (rPearson > 95% and 99% for CIs of main
and epistatic effects, respectively). More variation in CIs exist among mutations within
environments, with the most frequent mutations having the smallest CIs (ρSpearman =
−0.73,−0.67,−0.72,−0.72, in NODRUG, EFV, 3TC, and LPV, respectively, all P <
2.2×10−16). The size of the CI of a mutation thus depends on the amount of information
available in the dataset instead of its effect size.
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Randomization tests
We assessed the significance of the observed distributions of pleiotropy and epistatic
pleiotropy using different randomization tests. First, we tested for the significance of
the distributions of PDME and PDEP by randomizing the significant single and double
mutation effects among the 16 environments. For this, we built a 1859 × 16 matrix
for the ME data and a 556,125×16 matrix for the EP data, with 1s and 0s indicat-
ing significant and non-significant effects, respectively. Each matrix was shuﬄed 10,000
times from which we calculated the mean PD distributions. Second, to test for the
significance of the observed pattern of epistatic pleiotropy, we permuted the significant
MEs and EPs within each environment to generate random expectations of repertoire
composition while keeping the significance levels constant per environment for main and
epistatic effects. This randomization scheme allows us to test for the null hypothesis
of universal pleiotropy under which the epistatic pleiotropic effects (the private traits)
would be caused by the failure of detecting the corresponding main effects in the inter-
acting mutations. It thus tests whether the degree of non-additive epistatic pleiotropy
we observe is an artifact of the significance filtering we used. For this, we generated a
null distribution of the average number of private traits per interaction by performing
10,000 permutations of the 1859 main and 556,125 epistatic effects in each environment.
A P value associated with our point estimate of privateness can be readily obtained by
finding the empirical percentile from that bootstrapped distribution. Finally, we also
test whether the additivity of the interaction departs from its null expectation under the
same assumption.
Evolutionary statistics
Autonomy: The autonomy of a set of traits provides a measure of the integration of the
GP map: it represents the “proportion of evolvability that remains after conditioning
on other traits” (p1207 (Hansen and Houle, 2008)). GP maps with more integrated
modules of traits that are genetically less related to other such modules will thus have
higher autonomy. Corrected formula for autonomy a¯ is in Houle and Hansen (Hansen
and Houle, 2009).
Effective dimensionality: The effective dimensionality measures the contrast between the
first (λ1) and lower-rank eigenvalues (λi) of a covariance matrix and is nD =
∑
λi/λ1,
which can be interpreted as a weighted modularity measure representing independent
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modules with equal variance (Kirkpatrick, 2009).
Random skewers: the random skewers approach measures the average vector correlation
(average angle) of the selection response vectors of two covariance matrices submitted
to the same set of random selection vectors (Cheverud, 1996). We used 10,000 ran-
dom selection vectors (random skewers) to provide an estimate of the similarity in the
orientation of the covariance matrices in phenotype space.
The covariance matrices (M andG-matrices) were themselves generated by measuring all
pairwise environment covariances of within environment genotypic values (G-matrices)
or of all within environment significant mutational effects (M-matrices).
Parcellation
We computed the parcellation of the GP maps of the main (MP(ME)) and epistatic
(MP(EP)) effects with the parcellation statistic MP of Mezey et al. (Mezey et al., 2000).
Because the method requires a pre-defined set of modules, we first used the four modules
that we found in the phenotypic SEQ matrix, excluding the NODRUG environment.
The significance of the observed parcellation is evaluated against the parcellation of
randomized sets of ME and EP within environments (see Randomization Tests section
above).
To compare the parcellation of two networks of different sizes, we defined the following
standardized parcellation index:
MˆP =
MP −MP(rand)
SD(MP(rand))
,
which is the difference of observed parcellation to the mean random parcellation in units
of standard deviation.
All tests and analyses were performed with R v3.0.2 (R Core Team, 2012). PCA and
hierarchical cluster analysis were performed with prcomp and pvclust functions in R,
respectively.
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Tables
Table 1: Mean correlations within and between drug classes in sequence fitness.
Sequence data (SEQ) Main effects (ME) MEEP
PIs NRTIs NNRTIs PIs NRTIs NNRTIs PIs NRTIs NNRTIs
PIs 0.89 0.46 0.24 0.97 0.90 0.68 0.89 0.45 0.11
NRTIs 0.62 0.34 0.92 0.76 0.54 0.26
NNRTIs 0.92 0.88 0.89
Table 2: Covariance matrix comparisons. a) Effective dimensionality (nD, a measure
of modularity), and autonomy (a¯, a measure of genetic independence) of the
fitness covariance matrices. b) Same metrics for the mutational covariance
matrices of main (ME) and epistatic (EP) effects. c) Similarity of the ME,
MEEP and sequence (SEQ) fitness covariance matrices measured with Ran-
dom skewers (see Methods). When provided, values in parenthesis are the
2.5% and 97.5% bootstrap confidence limits of 10,000 bootstrap replicates
(see Supp. Information, PCA stability section).
a) G-matrices ME MEEP SEQ
nD 1.16 (1.157, 1.161) 2.08 (2.07, 2.09) 1.90 (1.89, 1.92)
a¯ 0.07 (0.072, 0.074) 0.16 (0.161, 0.163) 0.16 (0.159, 0.164)
b) M-matrices ME EP
nD 1.11 (1.072, 1.163) 1.10 (1.079, 1.129)
a¯ 0.05 (0.033, 0.072) 0.07 (0.066, 0.076)
c) Random skewers ME vs. MEEP ME vs. SEQ MEEP vs. SEQ
vector correlation 0.75 0.86 0.95
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Table 3: Proportion of significant main and epistatic effects that are fully pleiotropic
within drug class, and the average pleiotropic degree of significant mutations
relative to the maximum within-class pleiotropy (3 for NNRTI, and 6 for NRTI
and PI).
Drug class Full pleiotropy Relative pleiotropy
ME EP ME EP
NNRTI 0.49 0.52 0.73 0.76
NRTI 0.23 0.18 0.55 0.53
PI 0.38 0.29 0.65 0.6
Table 4: Abbreviations used in the text.
GP map genotype-phenotype map
ARV antiretroviral
a.-a. amino-acid
PI protease inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NNRTI non-nucleoside reverse transcriptase inhibitor
RT reverse transcriptase
PR protease
GKRR generalized kernel ridge regression
ME main effects
EP epistatic effects
PD pleiotropic degree
PDME pleiotropic degree of the main effects
PDEP pleiotropic degree of the epistatic effects
PDMEEP pleiotropic degree of the main and epistatic effects
M-matrix across-trait variance-covariance matrix of mutational effects
G-matrix across-trait variance-covariance matrix of genotype values
SEQ the G-matrix of observed genotypic values of samples viral a.-a. sequences
PCA principal component analysis
PC1 first principal component
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Figure 1: A) two mutations A and B affect each one trait when alone and affect each
two traits when together on the same sequence. The epistatic interaction be-
tween A and B thus has pleiotropy one and adds one trait to the trait reper-
toire of both A and B. B) Genotype-phenotype maps, with edges between
genes (empty circles) and traits (solid circles) representing the pleiotropic
effects of the genes. Parcellation results from the decrease of the number of
edges between trait modules (1-2 and 3-4). Integration is the reverse process
(re-drawn from Wagner and Altenberg, 1996). C) A mutation in gene a has
effects α1 on trait 1 and α2 on trait two. The genetic correlation between
α1 and α2 is rµ. The two square grids below represent the strength of the
among-trait correlations (genetic or phenotypic) resulting from the two GP
maps in (B). The modular phenotypes (on the right) have lower correlations
between modules (yellow) than within (red).
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Figure 2: Venn diagrams of the trait repertoires of two mutations (A and B) and their
interaction (A×B). Numbers represent traits (or environments) harboring
a significant main or epistatic effect of mutation A and B. Mutation A is
the focal mutation with PDME = 7 and repertoire = {1, 2, 5, 6, 7, 8, 10}.
Mutation B is the modifier mutation with PDME = 5 and repertoire
= {3, 4, 7, 8, 9}. The resulting interaction has PDEP,A×B = 6 with reper-
toire = {5, 6, 7, 9, 11, 13}, which thus partially overlaps with the repertoires
of A and B. The total pleiotropy of A in interaction with B is given by
PDMEEP,A×B = PDME,A ∪ PDEP,A×B = 10, as shown on the second row.
The repertoire of mutation A thus “gains” three traits in interaction with
B, of which one gives an additive increase (trait 9, added from mutation B’s
repertoire) and two give a non-additive increase (traits 11 and 13). Traits 11
and 13 are called the private traits of the interaction because they pertain
to the interaction’s repertoire only.
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Figure 3: Distributions of the pleiotropic degree (PD) of single (left) and double (right)
mutations. Open bars with red lining represent the random expectations of
the PD distributions obtained after 10,000 randomizations of significant main
and epistatic effects (see Methods).
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Figure 4: Relationship between the PD of single mutations and their average PDMEEP,
that is the average number of environments they affect across all their signif-
icant interactions. The solid line represents the 1:1 relationship.
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Figure 5: Heatmaps of the correlation matrices of fitness measurements of observed
sequence data (SEQ), estimates of main effects (ME), and estimates of main
and epistatic effects (MEEP) for the 15 drug environments and the drug-free
condition (ND). Drugs are ordered by class: ND (No Drug), NNRTIs (DLV,
EFV, NVP), NRTIs (3TC, ABC, D4T, DDI, TFV, ZDV), and PIs (AMP,
IDV, LPV, NFV, RTV, SQV).
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Figure 6: Principal component analysis of the G-matrices of sequence viral fitness
(SEQ), of the main effects only (ME), and of the main and epistatic ef-
fects (MEEP) of the mutations in reverse transcriptase and protease. Grey
dots indicate the relative positions of data points (virus log-fitness) within
the two principal components (PCs) and arrows symbolize the positions of
the original traits (drug environments) in this new phenotypic space. Drug
classes are highlighted with colors (ND = no-drug condition).
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